$27.72+1.05 (+3.94%)
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases.
| Metric (USD) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $26.04M↑ | $13.09M |
| Gross Profit | $14.46M↑ | $6.39M |
| Operating Income | -$12.35M↓ | -$8.55M |
| Net Income | -$21.32M↓ | -$7.66M |
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects an...
The aggressive growth fund investor was busy adding to some of her established stakes on Monday.
What Alamar Biosciences stock is telling you right now Alamar Biosciences (ALMR) has attracted fresh attention after recent trading left the stock with a last close of US$23.01 and a year to date gain of 4.59%, against mixed shorter term returns. For context, the stock was roughly flat over the past day, gained 0.17%, but declined 3.48% over the past week. Month and past 3 months performance data is not available, so short term momentum beyond these windows is harder to compare. See our...
Toast downgraded, Lowe's upgraded: Wall Street's top analyst calls